JPRN-UMIN000016265
Completed
未知
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myeloma - HCHSG-MM-214
ConditionsMultiple Myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- Sapporo Medical University Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Non\-secretory multiple myeloma or plasma cell leukemia. HIV\-, HBs\-, or HCV\-positive patients. Severe or uncontrolled hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension, infection, or psychiatric disorder. Patients with active and progressive malignancy. Women who are pregnant or in lactation. Those who are considered as inappropriate to register by attending physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39
Active, not recruiting
Phase 1
A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes - GFM- Aza-Ida-09Myelodysplastic syndromesMedDRA version: 12.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-017178-19-FRGroupe Francophone des Myélodysplasies56
Recruiting
Phase 2
uPBSCT with PTCY for ATadult T-cell leukemia/lymphomaJPRN-jRCTs031200375Fukuda Takahiro24
Recruiting
Not Applicable
Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomasJPRN-UMIN000011152B-SRIM Study Group38
Active, not recruiting
Phase 1
Study to evaluate efficacy and safety of sunitinib in patients with renal cell carcinoma who have progressed to first-line immunotherapy treatmentmetastatic renal clear cell carcinomaMedDRA version: 19.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-004011-12-ESSOGUG (Spanish Oncology Genitourinary Group)